Erelzi

Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
Understanding and using biosimilarsBiosimilars have the potential to lower the high costs of biologic treatments for patients suffering from chronic skin diseases. Although biosimilars have received FDA approval derms still have many questions about what they are and when they may be used appropriately. Patent wars and a lack of rules and regulations at the state level add to the confusion about using biosimilars.
Biosimilars and interchangeable biologics: News to watchBiosimilars in the United States are slowly gaining traction, but widespread confusion and legal barriers remain.
Five specialty pharmaceutical trends to watchApprovals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.
FDA approves etanercept biosimilar for psoriasis, psoriatic arthritisThe FDA approved the biosimilars Erelzi for plaque psoriasis and Enbrel for psoriatic arthritis.
What the new biosimilar means for U.S. healthcarePhysicians and pharmacists welcomed FDA’s recent approval of etanercept-szzs (Erelzi), a biosimilar to Amgen’s top-selling Enbrel for rheumatoid arthritis, plaque psoriasis, and other inflammatory conditions.